Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells

por Das, P M, Thor, A D, Edgerton, S M, Barry, S K, Chen, D F, Jones, F E
Publicado 2010

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells

por Lyu, Hui, Yang, Xiao He, Edgerton, Susan M., Thor, Ann D., Wu, Xiaoying, He, Zhimin, Liu, Bolin
Publicado 2015

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors

por Cittelly, Diana M, Das, Partha M, Spoelstra, Nicole S, Edgerton, Susan M, Richer, Jennifer K, Thor, Ann D, Jones, Frank E
Publicado 2010

Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling

por Jindal, Sonali, Gao, Dexiang, Bell, Pat, Albrektsen, Grethe, Edgerton, Susan M, Ambrosone, Christine B, Thor, Ann D, Borges, Virginia F, Schedin, Pepper
Publicado 2014

Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients

por Ihle, Claire L., Provera, Meredith D., Straign, Desiree M., Smith, E. Erin, Edgerton, Susan M., Van Bokhoven, Adrie, Lucia, M. Scott, Owens, Philip
Publicado 2019

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells

por Kim, Aeree, Liu, Bolin, Ordonez-Ercan, Dalia, Alvarez, Kathy M, Jones, Lynn D, McKimmey, Christine, Edgerton, Susan M, Yang, XiaoHe, Thor, Ann D
Publicado 2005

Glucose promotes breast cancer aggression and reduces metformin efficacy

por Wahdan-Alaswad, Reema, Fan, Zeying, Edgerton, Susan M, Liu, Bolin, Deng, Xin-Sheng, Arnadottir, Sigrid Salling, Richer, Jennifer K, Anderson, Steven M, Thor, Ann D
Publicado 2013

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

por Wang, Shuiliang, Huang, Jingcao, Lyu, Hui, Cai, Bo, Yang, Xiaoping, Li, Fang, Tan, Jianming, Edgerton, Susan M, Thor, Ann D, Lee, Choon-Kee, Liu, Bolin
Publicado 2013

Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells

por Zhao, Ming, Howard, Erin W., Parris, Amanda B., Guo, Zhiying, Zhao, Qingxia, Ma, Zhikun, Xing, Ying, Liu, Bolin, Edgerton, Susan M., Thor, Ann D., Yang, Xiaohe
Publicado 2017

Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells

por Lee, Harry, Saini, Nipun, Howard, Erin W., Parris, Amanda B., Ma, Zhikun, Zhao, Qingxia, Zhao, Ming, Liu, Bolin, Edgerton, Susan M., Thor, Ann D., Yang, Xiaohe
Publicado 2018

Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers

por Gari, Hamid H., Gearheart, Christy M., Fosmire, Susan, DeGala, Gregory D., Fan, Zeying, Torkko, Kathleen C., Edgerton, Susan M., Lucia, M. Scott, Ray, Rahul, Thor, Ann D., Porter, Christopher C., Lambert, James R.
Publicado 2016

Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases

por Contreras-Zárate, María J., Ormond, D. Ryan, Gillen, Austin E., Hanna, Colton, Day, Nicole L., Serkova, Natalie J., Jacobsen, Britta M., Edgerton, Susan M., Thor, Ann D., Borges, Virginia F., Lillehei, Kevin O., Graner, Michael W., Kabos, Peter, Cittelly, Diana M.
Publicado 2017

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

por Cochrane, Dawn R, Bernales, Sebastián, Jacobsen, Britta M, Cittelly, Diana M, Howe, Erin N, D’Amato, Nicholas C, Spoelstra, Nicole S, Edgerton, Susan M, Jean, Annie, Guerrero, Javier, Gómez, Francisco, Medicherla, Satyanarayana, Alfaro, Iván E, McCullagh, Emma, Jedlicka, Paul, Torkko, Kathleen C, Thor, Ann D, Elias, Anthony D, Protter, Andrew A, Richer, Jennifer K
Publicado 2014